Abstract
More than four decades after one U.S. Surgeon General reportedly declared it “time to close the book on infectious diseases,” drug-resistant pathogens have diminished the effectiveness of once-potent therapies.1 In the past three decades, newly described pathogens, including the human immunodeficiency virus (HIV), the severe acute respiratory syndrome (SARS) virus, and the H1N1 influenza virus, have caused pandemics, while old scourges from tuberculosis to cholera have persisted or resurged. Simultaneously, rising life expectancy and rapid social change have led to an increasing burden of chronic diseases for which we have effective therapies but inadequate innovation for delivering them efficiently to . . .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
